Company intelligence / Profile preview
Qingdao Growful Pharmaceutical
Qingdao, Shandong, Chinagrowful.com ↗
- Ownership
- Private
- Employees
- ~691
- Development stage
- Other
01
Overview
Qingdao Growful Pharmaceutical has several approved products: Xiaoer Feire Kechuan Granules, for bronchitis/common cold, approved in China since February 2020. Yinqiao Jiedu Granules, for common cold, approved in China since January 2020. Polysaccharide Iron Complex, for iron deficiency anemia, first approved in the United States on January 10, 2017. The company also markets YangXinShi for myocardial infarction. No recent clinical trial activity is reported beyond these approvals.
- Therapeutic areas
- NeurologyPulmonologyInfectious DiseasesHematologyCardiovascular
- Modalities
- Herbal medicineSmall molecule drugPolysaccharide iron complex
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Qingdao Growful Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingdao Growful Pharmaceutical.